{"id":"NCT01576341","sponsor":"Sandoz","briefTitle":"HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)","officialTitle":"Open Label, Single Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of HX575 Epoetin Alfa in the Treatment of Anemia Associated With Chronic Kidney Disease in Pre-dialysis and Dialysis Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-04","primaryCompletion":"2014-10","completion":"2015-06","firstPosted":"2012-04-12","resultsPosted":"2017-06-19","lastUpdate":"2017-06-19"},"enrollment":417,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Kidney Disease"],"interventions":[{"type":"DRUG","name":"HX575 epoetin alfa (Sandoz)","otherNames":["Binocrit®, Epoetin alfa HEXAL®, Novicrit®, Abseamed®"]}],"arms":[{"label":"HX575 epoetin alfa (Sandoz)","type":"EXPERIMENTAL"}],"summary":"The study will assess the immunogenicity, safety, and efficacy of HX575 epoetin alfa administered subcutaneously (s.c.) in patients suffering from anemia due to chronic kidney disease (CKD)","primaryOutcome":{"measure":"Anti-Erythropoietin (EPO) Antibodies","timeFrame":"52 weeks","effectByArm":[{"arm":"HX575","deltaMin":1.7,"sd":null}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":9},"locations":{"siteCount":50,"countries":["Germany","Italy","Poland","Romania","Russia","Turkey (Türkiye)","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":103,"n":416},"commonTop":["Hypertension","Renal failure chronic","Hyperkalaemia","Nasopharyngitis","Pneumonia"]}}